TABLE 5 

Relation of ex vivo cytokine concentrations to follow-up of subjects

Result or parameter at follow-upEx vivo cytokine concn (pg/ml) (range) or the P valuea
GM-CSFIL-1βIFN-γIL-2IL-13TNF-α
Outcome
    Improved (n = 18)244 (0–1,744)465 (0–3,998)303 (0–1,854)562 (1–2,013)42 (0–854)6,689 (1–29,374)
    Not improved (n = 8)182 (3–1,478)385 (3–3,067)859 (12–1,847)771 (11–2,058)48 (3–122)465 (3–6,692)
    value0.8681.000.3170.6570.7810.085
IDCF titer
    Positive (n = 12)360 (5–1,478)364 (16–3,998)560 (23–1,847)679 (28–2,058)60 (5–301)6,662 (57–29,374)
    Negative (n = 14)170 (0–1,744)470 (0–2,084)211 (0–1,854)571 (1–2,013)26 (0–854)809 (1–14,206)
    value0.3040.4410.1360.4720.3820.165
Chest imaging
    Improved (n = 15)324 (5–1,744)455 (0–3,453)311 (12–1,854)1,072 (14–2,058)52 (2–854)3,785 (57–24,253)
    Not improved (n = 10)126 (0–1,478)369 (1–3,998)448 (0–1,180)499 (1–2,013)36 (0–104)905 (1–29,374)
    value0.1200.9120.4710.1830.2220.346
Antifungal therapy
    Yes (n = 12)232 (0–1,478)456 (1–3,998)211 (0–1,687)166 (1–1,913)36 (0–158)2,206 (1–29,374)
    No (n = 14)225 (3–1,744)435 (0–1,697)595 (12–1,854)1,053 (11–2,058)67 (2–854)5,200 (3–8,908)
    P value0.7970.4400.1810.0310.3040.877
  • a The P values are shown in italic type in the table. The italic boldface P value indicates statistical significance.